|
In a recent Clinical Trial Magnifier publication, we studied the globalization of industry-sponsored clinical trials based on the US trial registry five-year set of data, i.e. from January 1, 2006 to December 31, 2010. North America and Europe have jointly lost 1.1% of the number of study sites over the two 2.5-year periods of observation. The number of sites has increased in both Asia and East Europe during the two periods of observation by 1.2% and 0.4%, respectively while the number has decreased in Latin America and Africa each by 0.4%. East Europe was still the most popular emerging region for industry-sponsored clinical trials with 12.5% of the total number of sites, while Asia now contributes 9.7% of all sites globally. One recent, obvious trend is thus that the industry has an increased focus on North East Asia and East Europe, taking the attention from established regions and Latin America. |





















